Skip to main content
African Health Sciences logoLink to African Health Sciences
. 2018 Mar;18(1):102–110. doi: 10.4314/ahs.v18i1.14

Clinical implication of smoking among patients with schizophrenia at a Tertiary Institution in South East Nigeria

Chinyere Aguocha 1, Richard Uwakwe 2, Emmanuel Olose 3, Kennedy Amadi 4, Gabriel Onyeama 4, Chukwuma Duru 5
PMCID: PMC6016984  PMID: 29977263

Abstract

Background

The chronic and debilitating nature of schizophrenia creates a disease with marked clinical and economic consequences. Smoking in schizophrenia appears to be associated with increased psychopathology and disability.

Objective

The aim of this study was to determine if cigarette smoking in schizophrenia is associated with increased disability and psychopathology.

Materials and methods

This was a cross-sectional descriptive study in which 367 out-patients with International Classification of Diseases (ICD) 10 diagnosis of schizophrenia were recruited. Socio-demographic questionnaire, Present State Examination (PSE) 10, Positive And Negative Syndrome Scale (PANSS) and World Health Organization Disability Assessment Schedule (WHODAS) were administered. Data was analyzed using a software package SPSS version 15.

Results

There was no significant difference in the mean PANSS scores of smokers and non-smokers. Current smoking was associated with increased disability (F=5.39, p=0.02). Total PANSS score significantly predicted disability F(3,71=5.60, p=0.002, R2=0.19). There was no significant association between positive or negative symptoms and being a smoker or non-smoker.

Conclusion

The results of this study revealed that smoking in Nigerian schizophrenia patients is associated with significant disability. Measures should be put in place to discourage cigarette smoking among Nigerian patients with schizophrenia.

Keywords: Schizophrenia, smoking, psychopathology, disability, Nigeria

Introduction

Schizophrenia has been ranked as one of the ten most debilitating diseases worldwide and accounts for 1.1% of the total disability-adjusted life years and 2.8% of years lived with disability1,2. Studies that compared disability across mental disorders showed that schizophrenia ranked ahead of dementia, depression, obsessive compulsive disorder, alcoholism and bipolar affective disorder3,4,5. Schizophrenia leads to a breakdown in interpersonal and occupational achievement6. Psychopathology has been recognized as one of the most important factors in disability7. Disability in schizophrenia persists for years after symptom remission8. Disability affects social participation mainly and is associated with age of the patient and severity of psychotic symptoms9.

Nicotine is by far the most prevalent drug abused by schizophrenia patients and it increases mortality rate and financial burden incurred in the course of treatment10,11,12,13. The effect of smoking on the outcome of schizophrenia has been rather controversial10,13,14,15.

Understanding the effects of smoking on disability and psychopathology in schizophrenia would help develop appropriate evidence based biological and psychosocial interventions for these patients. No studies investigating the influence of cigarette smoking on the clinical expression of schizophrenia as measured via Positive And Negative Syndrome Scale (PANSS) and disability via World Health Organization Disability Assessment Schedule (WHODAS) have been reported in the Nigerian South East population. This article therefore explored the hypothesis that smoking leads to increased psychopathology and disability among patients with schizophrenia in South East Nigeria.

Subjects and methods

This study was carried out at the Federal Neuropsychiatric Hospital located at Enugu, South Eastern region of Nigeria. The hospital provides services mainly to patients from the five states that make up the South Eastern part of Nigeria. A total of 367 patients with schizophrenia from the out-patient department of the hospital were studied.

This was a hospital based descriptive cross-sectional study. Three hundred and sixty seven patients with International Classification of Diseases (ICD 10) diagnosis of schizophrenia confirmed with Present State Examination 10 (PSE-10) and not too ill to undergo the interview were included in the study. Patients were excluded if they declined to take part and if by self report or from medical records it was found that they had any other important disorder besides schizophrenia.

WHODAS II 12 Item Version was used to measure disability. It is a measure of global disability. The participants were asked to rate the level of difficulty they experienced (none 1, mild 2, moderate 3, severe 4, extreme 5), taking into consideration the ease in which they performed a given activity. Simple sum scoring method was used to calculate total disability. The internal consistency and test-retest reliability of the overall WHODAS 2.0 is high. WHODAS II has been used previously in Nigeria16,17.

PANSS is a 30-item questionnaire that is used to assess patients' current mental state. The PANSS includes 30 items on 3 subscales: 7 items covering positive symptoms, 7 covering negative symptoms and 16 covering general psychopathology. Each item is scored on a seven-point item-specific Likert scale ranging from 1 to 7. Total Scores for the three scales were arrived at by summation of ratings across the component items. In addition, a composite scale was scored by subtracting negative from positive scores yielding a bipolar index (positive and negative), which was essentially a difference in score reflecting the degree of predominance of one syndrome in relation to the other18. Those who had equal scores in both scales were regarded as neither positive nor negative. PANSS has excellent internal consistency and inter-rater reliability. PANSS has been used previously in Nigeria19.

Patients who met the ICD 10 diagnosis of schizophrenia, made by a consultant psychiatrist or a senior trainee Psychiatrist (Resident Doctor) were selected. This diagnosis was confirmed using the schizophrenia schedule of PSE-10. Thereafter the socio-demographic questionnaire was administered to elicit information about age, gender, marital status, educational attainment employment status and age at onset of illness. For those who accepted ever smoking cigarettes, cigar or pipe in their life, PSE-10 smoking schedule was administered. The PSE-10 definition of “ever smoked” was adopted as the operational identification of “life time smoker”, whereas “current smoking” refered to “having smoked in the past four weeks”, irrespective of frequency or number of cigarettes20. Those who smoked 1–10 cigarettes per day were classified as light smokers while those who smoked more than 10 cigarettes everyday were classified as heavy smokers21,22. Early onset schizophrenia was classified as schizophrenia with onset before 18 years while late onset was above 18 years23.

We measured and quantified the severity of psychotic symptoms of schizophrenia using Positive and Negative Syndrome Scale (PANSS) in all the participants. The total PANSS Score was recorded. Finally World Health Organization Disability Assessment Schedule II 12 item version (WHODAS II) was administered to measure disability in the previous month in all the participants. The participants' WHODAS scores were dichotomized (yes/no) such that participants' with a total score of 12 were regarded as having no disability while scores above 12 indicated presence of disability24. Daily doses of neuroleptics were converted into chlorpromazine equivalents (CPZ-eqs) for ease of statistical analysis.

Data was cleaned manually and analyzed using Computer software (Statistical Package for the Social Sciences Version 15). Statistical testing was conducted at the 5% significance level and 95% confidence interval. Gender, educational level, age of the participants, age of onset of schizophrenia, marital status, religion and employment status were presented as simple frequencies and percentages. Chi-square was used to test association between symptoms of schizophrenia and smoking status. PANSS score, number of cigarettes smoked per day, severity of smoking and dosage of anti-psychotic medications were entered into a multivariable regression model to adjust for confounders and identify predicting associations between these variables and disability scores. Associations between the mean number of cigarettes smoked per day and psychopathology; and between the mean number of cigarettes smoked per day and disability were tested using t-test. A p-value <0.05 was considered significant.

This study was approved by the Ethics Committee of the Federal Neuropsychiatric Hospital Enugu. Voluntary informed consent was sought and obtained from all the participants before recruitment into the study.

Results

Table 1 shows the characteristics of the participants. A total of 367 participants were included in the study. Most of the participants, 189 (51.5%) were females. Mean age of the participants was 34.1 ± 9.9 years. Mean age of onset of schizophrenia was 25.3 ± 6.5 years. The mean duration of schizophrenia illness was 8.76 ± 7.54. Most of the participants, 241 (65.7%) had never been married. Most of the participants had late onset schizophrenia (85.3%). One hundred and seventy six (48.0%) of the participants had a predominance of negative symptoms.

Table 1.

Socio-demographic and clinical characteristics of participants

Variables N Percent (%)
Gender
Female 189 51.5
Male 178 48.5
 
Age (years)
10–29 134 36.5
30–49 196 53.4
50–69 37 10.1
Mean ± S.D 34.1 ± 9.9
 
Age of onset (years)
Early onset schizophrenia 54 14.7
Late onset schizophrenia 313 85.3
Mean ± S.D 25.3 ± 6.5
 
Duration of illness (years)
Mean ± S.D 8.76 ± 7.54
 
Marital status
Married 87 23.7
Never married 241 65.7
Divorced 32 8.7
Widowed 7 1.9
 
Educational level
No formal education 16 4.4
Primary education 59 16.1
Secondary education 203 55.3
Tertiary education 89 24.2
 
Religion
Christian 364 99.2
Islam 3 0.8
 
Employment status
Employed 164 44.7
Unemployed 203 55.3
Smoking status
Ever smoked 95 25.9
Currently smokes 75 20.4
 
Severity of smoking
Light smokers 2 2.7
Heavy smokers 73 97.3
 
Symptoms of schizophrenia
Predominance of positive symptoms 113 30.7
Predominance of negative symptoms 176 48.0
Equal dominance 78 21.3
Total PANSS Score 45.01±11.89
 
Disability
Yes 313 85.3
No 54 14.7
 
Mean disability 22.03 ± 8.35

Part of Table 1 was adapted from Table 1 of ‘Aguocha C.M., Aguocha J.K., Monday Igwe, Uwakwe R.U., Onyeama G.M. Prevalence And Correlates Of Cigarette Smoking Among Patients With Schizophrenia In South East Nigeria. Acta Psychiatrica Scandinavica 11 SEP 2014 | DOI: 10.1111/acps.12334

Table 2 shows that current smokers had a significantly higher mean WHODAS score of 24.0 ±8.1 compared to 21.5 ±8.3 for those that were not current smokers (F= 5.39, p= 0.02). The current smokers had a higher mean disability score (24.0 ±8.1) compared to the lifetime smokers (22.9 ±8.1). Among all the participants studied, the mean PANSS score was 45.01±11.89 with range 30–94. There was no significant difference in the mean PANSS scores of those who had never smoked and current and lifetime smokers. Multiple regression was used to predict disability from Total PANSS score, dosage of antipsychotics and number of cigarettes smoked per day. Total PANSS score significantly predicted disability β=0.35, F (3, 71 = 4.16, p=0.00, R2 = 0.19). There was a weak positive linear relationship between mean WHO-DAS Score and total PANSS Score (r=0.43, p= 0.0001) and between dosage of anti-psychotics prescribed and number of cigarettes smoked daily (r=0.27, p=0.009) among the current smokers.

Table 2.

Mean WHODAS and PANSS scores among the participants.

Variable Mean Standard
deviation
Test
statistic
p-value

WHODAS
Ever smoked
Yes 22.9 8.1 F= 1.52 p=0.22
No 21.7 8.4

Currently smokes
Yes 24.0 8.1 F= 5.39 p=0.02*
No 21.5 8.3

PANSS
Ever smoked
Yes 44.2 9.5 F=0.6 p= 0.44
No 45.3 12.6

Currently smokes
Yes 44.8 10.0 F=0.04 p=0.85
No 45.1 12.3

F=One Way ANOVA

Table 3 showed greater rate of smoking among those with predominantly negative symptoms. There was no significant association between number of cigarettes smoked per day, disability scores (t=−1.04, p=0.30) and PANSS composite scores (t=−0.73, p=0.47).

Table 3.

Association between smoking, disability and clinical psychopathology

Variable Frequency Percent Stat p-value
Lifetime smoking
Yes (%) No (%)
Predominance of Negative symptoms 50 (52.6) 126 (46.3) X2 =5.72 p=0.06
Predominance of Positive symptoms 33 (34.8) 80 (29.4) d.f=2
Equal dominance 12 (12.6) 66 (24.3)
Current smoking
Predominance of Negative symptoms 41 (54.7) 135 (46.2) X2 =4.88 p=0.09
Predominance of Positive symptoms 25 (33.3) 88 (30.2) d.f=2
Equal dominance 9 (12.0) 69 (23.6)
Mean No. of cigarettes smoked per day and disability
Disability N (%) Mean No. of
cigarettes smoked
per day
Stat p-value
Yes 71 (94.7) 3.90 ± 3.62 t= −1.04 p=0.30
No 4 (5.3) 2.00 ± 0.82
Mean No. of cigarettes smoked perday and psychopathology
N (%) Mean No. of
cigarettes smoked
per day
Stat p-value
Predominance of Positive symptoms 25 3.56 ± 3.26 t= −0.73 p=0.47
Predominance of Negative symptoms 41 4.24 ± 4.23

Discussion

Research regarding the clinical characteristics of cigarette smokers with schizophrenia has produced mixed results, which may be attributed to methodological and sampling differences25. Reduced rate of smoking in these patients compared to those in developed countries, differing antipsychotic medications, dosage of anti-psychotics and male to female ratio can account for this. A high rate of heavy smoking (97.3%) was found among the participants in this study. It was higher than 52% previously reported26. This difference can be attributed to variations in the cut off scores for heavy smoking26. Countries, especially developed countries with higher rate of smoking may tend to use a higher cut off20.

Most of the participants (48%) had a predominance of negative symptoms. This is higher than 25% and 15.8% reported in some other studies27,28. This may be due to differences in sampling methods, help seeking behavior, duration of untreated psychosis, long schizophrenia illness and effect of medications leading to an increase in negative symptoms27,28. Long duration of untreated psychosis found in developing countries, has been recorded among patients with predominantly negative symptoms28. Current smoking was demonstrated to be significantly associated with disability. This is consistent with what has been found in some other studies29,30. This has been attributed to smoking being a marker for a more severe schizophrenic illness25,31.

There was no significant association between smoking status and psychopathology. This is consistent with what has been previously reported32. In fact, contrary to what was expected, smokers had lesser total clinical psychopathology scores compared to non-smokers. This may be due to smoking inducing relaxation and pleasurable feelings and reducing anxiety, anger and depression33. These effects may have greater importance among patients with schizophrenia because their other sources of pleasure and satisfaction are likely diminished33. This supports what has been reported previously that there is little evidence to support that tobacco use worsens the symptoms of schizophrenia14,34.

Smoking status was not significantly associated with predominance of positive or negative symptoms. This agrees with reports of no statistically significant differences between schizophrenia smokers and non-smokers with regard to the severity of negative symptoms30,35,36. Some other studies have reported that patients with more severe negative symptoms tend to smoke more to alleviate the symptoms of schizophrenia and that more severe negative symptoms were independently associated with current smoking37,38,39. Reduced dopamine neurotransmission associated with chronic substance may be the cause of increased negative symptoms among these patients10. Clinical psychopathology was independently associated with disability among current smokers. This supports studies that have reported that though modest, increased psychopathology was associated with increased disability40. It also agrees with reports of total PANSS and Brief Psychiatric Rating Scale (BPRS) scores having a significant positive correlation with disability13,41.

Limitation

The study was a cross-sectional non-population representative study with small number of participants, it included only out-patients with schizophrenia, so its results cannot easily be generalized to the entire population. Secondly, the estimation of cigarette smoking habits was by self-report. A hundred percent reliability cannot be guaranteed. Assessing nicotine dependence with more specific methods, such as pack- year smoking history and Fagerstrom test for nicotine dependence is required in further studies.

Conclusion

Smoking in Nigerian schizophrenia patients is associated with significant disability and psychopathology. It calls for urgent measures to be implemented to discourage smoking among Nigerian patients with schizophrenia.

Conflict of interest

There is no conflict of interest.

References

  • 1.The WHO World Health Report 2001: New Understanding, New Hope. 2001. [1st June 2016]. [Google Scholar]
  • 2.World Health Organization, author. Prevalence of tobacco smoking in Nigeria. Geneva: WHO; 2001. [1st June 2016]. [Google Scholar]
  • 3.Marneros A, Diester A, Rhode A. Psychopathological and social status of patients with affective, schizophrenic and schizoaffective disorders after long-term course. Acta Psychiatric Scand. 1990;82:352–358. doi: 10.1111/j.1600-0447.1990.tb01400.x. PubMed. [DOI] [PubMed] [Google Scholar]
  • 4.Bowie CR, Depp C, McGrath JA, Wolyniec P, Mausbach BT, Thornquist MH, et al. Prediction of Real-World Functional Disability in Chronic Mental Disorders: A Comparison of Schizophrenia and Bipolar Disorder. Am J Psychiatry. 2010;167:1116–1124. doi: 10.1176/appi.ajp.2010.09101406. PubMed. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Shihabuddeen I, Harpreet M, Pinto AP. Disability in Schizophrenia and Bipolar Mood disorder at a General Hospital Psychiatry Unit. Delhi Psychiatry Journal. 2011;14(2):258–261. [Google Scholar]
  • 6.Williams JM, Foulds J. Successful Tobacco Dependence Treatment in Schizophrenia. Am J Psychiatry. 2007;164:222–227. doi: 10.1176/ajp.2007.164.2.222. PubMed. [DOI] [PubMed] [Google Scholar]
  • 7.Jablensky A. Epidemiology of schizophrenia: The global burden of disease and disability. European Archives of Psychiatry & Clinical Neuroscience. 2000;250(6):274–285. doi: 10.1007/s004060070002. [DOI] [PubMed] [Google Scholar]
  • 8.Wiersma D, Wanderling J, Dragomirecka E, Ganev K, Harrison G, An Der Heiden W, Nienhuis F, et al. Social disability in schizophrenia: its development and prediction over 15 years in incidence cohorts in six European centres. Psychol Med. 2000;30:1155–1167. doi: 10.1017/s0033291799002627. PubMed. [DOI] [PubMed] [Google Scholar]
  • 9.Wancata J, Freidl M, Friedrich F, Matschnig T, Unger A, Stockinger A, Dantendorfer K. Disability in schizophrenic disorders. European Psychiatry. 2009;24(S1):S209. [Google Scholar]
  • 10.Volkow N. Substance Use Disorders in Schizophrenia—Clinical Implications of Comorbidity. Schizophrenia Bulletin. 2009;35(3):469–472. doi: 10.1093/schbul/sbp016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Wette R, Konig H, Leidl R. The Costs of Health Damage and Productivity Losses Attributable to cigarette Smoking in Germany. European J of Public Health. 2006;10(1):31–38. PubMed. [Google Scholar]
  • 12.Lichtermann D, Ekelund J, Pukkala E, Tanskanen A, Lönnqvist J. Incidence of Cancer Among Persons With Schizophrenia and Their Relatives. Arch Gen Psychiatry. 2001;58(6):573–578. doi: 10.1001/archpsyc.58.6.573. [DOI] [PubMed] [Google Scholar]
  • 13.Goff D, Henderson D, Amico E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side-effects. American Journal of Psychiatry. 1992;149:1189–1194. doi: 10.1176/ajp.149.9.1189. [DOI] [PubMed] [Google Scholar]
  • 14.George TP, Vessicchio JC, Termine A, Sahady DM, Kosten TR. Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology. 2002;26:75–85. doi: 10.1016/S0893-133X(01)00296-2. [DOI] [PubMed] [Google Scholar]
  • 15.George TP. Neurobiological links between nicotine addiction and schizophrenia. J Dual Diagn. 2007;3:27–42. [Google Scholar]
  • 16.Ogundele AT. Risk factors for disability among depressed elderly people living in a Nigerian community. 2009. pp. 28–40. Dissertation submitted to the West African college of Physicians. [Google Scholar]
  • 17.Bella TT, Omigbodun O. Social phobia in Nigerian university students: prevalence, correlates and co-morbidity. Soc Psychiatry Psychiatr Epidemiol. 2009;44:458. doi: 10.1007/s00127-008-0457-3. [DOI] [PubMed] [Google Scholar]
  • 18.Kay SR, Fiszbein A, Opler LA. “The positive and negative syndrome scale (PANSS) for schizophrenia”. Schizophr Bull. 1987;13(2):261–276. doi: 10.1093/schbul/13.2.261. [DOI] [PubMed] [Google Scholar]
  • 19.Adeosun I. Correlates of Caregiver Burden among Family Members of Patients with Schizophrenia in Lagos, Nigeria Schizophr Res Treatment. 2013. Article ID 353809, 7 pages. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Aguocha CM, Aguocha JK, Igwe M, Uwakwe RU, Onyeama GM. Prevalence and correlates of cigarette smoking among patients with schizophrenia in southeast Nigeria. Acta Psychiatr Scand. 2014:1–7. doi: 10.1111/acps.12334. [DOI] [PubMed] [Google Scholar]
  • 21.Biener L, Albers AB. Young adults: Vulnerable new targets of tobacco marketing. American Journal of Public Health. 2004;94:326–330. doi: 10.2105/ajph.94.2.326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Hajek P, West R, Wilson J. Regular smokers, lifetime very light smokers, and reduced smokers: comparison of psychosocial and smoking characteristics in women. Health Psychol. 1995;14:195–201. doi: 10.1037//0278-6133.14.3.195. PubMed. [DOI] [PubMed] [Google Scholar]
  • 23.Clemmensen L, Vernal DL, Steinhausen HC. “A systematic review of the long-term outcome of early onset schizophrenia”. BMC Psychiatry. 2012;12:150. doi: 10.1186/1471-244X-12-150. PMC 3521197 Freely accessible. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Herran A, Santiago A, Sandoya M, Fernandez M, Dıez-Manrique J, Vazquez-Barquero J. Determinants of smoking behaviour in outpatients with schizophrenia. Schizophrenia Research. 2000;41:373–381. doi: 10.1016/s0920-9964(99)00082-1. [DOI] [PubMed] [Google Scholar]
  • 25.Yan-Min X, Hong-Hui C, Fu L, Fang D, Xiao-Bo L, Hai-Chen Y, Li-Guo Q, Jin-Hong G, Tie-Bang L. Prevalence and Correlates of Cigarette Smoking among Chinese Schizophrenia Inpatients Receiving Antipsychotic Mono-Therapy. PLoS One. 2014;9(2):e88478. doi: 10.1371/journal.pone.0088478. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Woolhand J, Lasser K, Boydler S, Himmelstein D, McCormick D, Bor D. Smoking and mental illness. A population based prevalence study. JAMA. 2000;284:2606–2610. doi: 10.1001/jama.284.20.2606. PubMed. [DOI] [PubMed] [Google Scholar]
  • 27.Granö N, Lindsberg J, Karjalainen M, Grönroos P, Blomberg A. Duration of untreated psychosis is associated with more negative schizophrenia symptoms after acute treatment for first-episode psychosis. Clinical Psychologist. 2010;14(1):10–13. [Google Scholar]
  • 28.Odinka PC, Ndukuba AC, Muomah RC, Oche M, Osika MU, Bakare MO, Agomoh AO, Uwakwe R. Positive and negative symptoms of schizophrenia as correlates of help-seeking behaviour and the duration of untreated psychosis in south-east Nigeria. SAJP. 2014 Nov;20(4) http://dx.doi.org/10.7196/sajp.536. [Google Scholar]
  • 29.McEvoy J, Allen P, Trina B. Substance abuse (including nicotine) in schizophrenic patients. Current Opinion in Psychiatry. 2003;16(2):199–205. [Google Scholar]
  • 30.Hou Y, Xiang Y, Yan F, Ungvari G, Dickerson F, Chiu H, Lai K, Lee E, Li W, Li W, Zhu Y, Dixon L. Cigarette smoking in community-dwelling patients with schizophrenia in China. Journal of Psychiatric Research. 2011;45(12):1551–1556. doi: 10.1016/j.jpsychires.2011.07.011. [DOI] [PubMed] [Google Scholar]
  • 31.De Leon J. Smoking and vulnerability for schizophrenia. Schizophrenia Bulletin. 1996;22:405–409. doi: 10.1093/schbul/22.3.405. [DOI] [PubMed] [Google Scholar]
  • 32.Barnes M, Lawford BR, Burton SC, Heslop KR, Noble EP, Hausdorf K, Young RM. Smoking and schizophrenia: is symptom profile related to smoking and which antipsychotic medication is of benefit in reducing cigarette use? Aust N Z J Psychiatry. 2006 Jun-Jul;40(6–7):575–580. doi: 10.1080/j.1440-1614.2006.01841.x. [DOI] [PubMed] [Google Scholar]
  • 33.Edward R, Lyon MSA. Review of the Effects of Nicotine on Schizophrenia and Antipsychotic Medications. Psychiatr Serv. 1999;50:1346–1350. doi: 10.1176/ps.50.10.1346. [DOI] [PubMed] [Google Scholar]
  • 34.Ziedonis DM, George TP. Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophrenia Bulletin. 1997;23:247–254. doi: 10.1093/schbul/23.2.247. [DOI] [PubMed] [Google Scholar]
  • 35.Zhang XY, Chen DC, Xiu MH, Haile CN, He SC, Luo X, Zuo L, Rosenheck R, Kosten TA, Kosten TR. Cigarette smoking, psychopathology and cognitive function in first-episode drug-naive patients with schizophrenia: a case-control study. Psychol Med. 2013 Aug;43(8):1651–1660. doi: 10.1017/S0033291712002590. [DOI] [PubMed] [Google Scholar]
  • 36.Tang YL, George TP, Mao PX, Cai ZJ, Chen Q. Cigarette smoking in Chinese male in patients with schizophrenia: a cross-sectional analysis. J Psychiatr Res. 2007;41:43–48. doi: 10.1016/j.jpsychires.2005.10.009. [DOI] [PubMed] [Google Scholar]
  • 37.Ziedonis D, Kosten T, Glazer W, Frances R. Nicotine dependence and schizophrenia. Hospital and Community Psychiatry. 1994;45:204–206. doi: 10.1176/ps.45.3.204. [DOI] [PubMed] [Google Scholar]
  • 38.Hall R, Duhamel M, McClanahan R, Miles G, Nason C, Rosen S, et al. Level of functioning, severity of illness, and smoking status among chronic psychiatric patients. J Nerv Men Dis. 1995;183:468–471. doi: 10.1097/00005053-199507000-00008. [DOI] [PubMed] [Google Scholar]
  • 39.Beratis S, Katrivanou A, Gourzis P. Factors affecting smoking in schizophrenia. Comprehensive Psychiatry. 2001;45:393–402. doi: 10.1053/comp.2001.26273. [DOI] [PubMed] [Google Scholar]
  • 40.Bowie CR, Reichenberg A, Patterson TL, Heaton RK, Harvey PD. Determinants of real-world functional performance in schizophrenia subjects. Correlations with cognition, functional capacity and symptoms. Am J Psychiatry. 2006;163:418–425. doi: 10.1176/appi.ajp.163.3.418. PubMed. [DOI] [PubMed] [Google Scholar]
  • 41.Manabendra M, Uttam M, Amitava D, Shantanu D, Nirmal K. Disability in Persons with Schizophrenia: Its Correlation with Psychopathology and Socio-Demographic Profile. Indian Medical Gazette. 2013:335–344. [Google Scholar]

Articles from African Health Sciences are provided here courtesy of Makerere University Medical School

RESOURCES